Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial (Q42945870)
Jump to navigation
Jump to search
scientific article published on September 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial |
scientific article published on September 2010 |
Statements
1 reference
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial (English)
1 reference
Everett E Vokes
1 reference
Pasi A Jänne
1 reference
Neal Ready
1 reference
Jeffrey Bogart
1 reference
Thomas Dipetrillo
1 reference
Jennifer Garst
1 reference
Stephen Graziano
1 reference
Lin Gu
1 reference
Xiaofei Wang
1 reference
Mark R Green
1 reference
Cancer, Leukemia Group B, Chicago, IL
1 reference
1 September 2010
1 reference
1 reference
Identifiers
1 reference